@article{53ffc3b2d0754b23b4653c5c171ae945,
title = "Endpoint surrogacy in oncology Phase 3 randomised controlled trials",
abstract = "Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.",
author = "Jianrong Zhang and Pilar, {Meagan R.} and Xiaofei Wang and Jingxia Liu and Herbert Pang and Brownson, {Ross C.} and Colditz, {Graham A.} and Wenhua Liang and Jianxing He",
note = "Funding Information: Funding information J.L. and G.A.C. acknowledge the support for the Siteman Cancer Center from the National Institutes of Health (NIH) Grant P30 CA 091842. Publisher Copyright: {\textcopyright} 2020, Cancer Research UK.",
year = "2020",
month = aug,
day = "4",
doi = "10.1038/s41416-020-0896-5",
language = "English",
volume = "123",
pages = "333--334",
journal = "British Journal of Cancer",
issn = "0007-0920",
number = "3",
}